Incannex Healthcare (IXHL) Non Operating Interest Expenses (2024 - 2025)
Incannex Healthcare's (IXHL) quarterly Non Operating Interest Expenses came in at -$5000.0 in Q4 2025, up 82.14% year-over-year from -$2745.1 in Q4 2024, and little changed quarter-over-quarter from -$5000.0 in Q3 2025.
Powered by 
Analysis
Incannex Healthcare (IXHL) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends
Incannex Healthcare has disclosed Non Operating Interest Expenses across 2 years of filings, most recently posting -$5000.0 for Q4 2025.
- In Q4 2025, Non Operating Interest Expenses rose 82.14% year-over-year to -$5000.0; the TTM figure through Dec 2025 stood at $122000.0 (changed N/A YoY), while the FY2025 annual figure was $303000.0, changed N/A from the prior year.
- Non Operating Interest Expenses came in at -$5000.0 for Q4 2025 at Incannex Healthcare, roughly flat from -$5000.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $132000.0 in Q1 2025 to a low of -$28000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.62 Bn | 625.86 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 442.20 Bn | 435.63 Bn | 12.70 Bn | - |
| 3 | Merck | 366.42 Bn | 359.28 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.80 Bn | 259.11 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 159.12 Bn | 147.42 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.39 Bn | 20.85 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.45 Bn | 18.78 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Incannex Healthcare | 41.37 Mn | 41.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -5,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Mar 31, 2025 | 132,000.00 |
| Dec 31, 2024 | -28,000.00 |
| Sep 30, 2024 | -28,000.00 |